OPKO Health, Inc. (OPK)

Over the past six months, OPKO Health's stock price has decreased by 4.5%, while its industry and the S&P 500 have increased. Key events include the sale of BioReference Health's oncology assets to Labcorp, a $100 million share repurchase program authorized in November 2024 and an additional $100 million authorized in May 2025, FDA approval for the 4Kscore test, Q3 2025 earnings reporting $0.03 EPS, and advancements in its pharmaceutical pipeline through strategic partnerships.

Specific demand seasonality for OPKO Health's products and services is not explicitly detailed. Diagnostic testing volumes might fluctuate with seasonal illnesses, and pharmaceutical sales could see some seasonality depending on the indications they treat. A more in-depth analysis of sales trends for individual products and testing services would be required to determine specific demand seasonality.

OPKO Health, Inc. is a global healthcare company based in Miami, Florida, specializing in diagnostics, pharmaceuticals, and biologics. It operates through Laboratory Services and Pharma Services & Products segments. BioReference Laboratories, a subsidiary, offers a range of testing services, including the 4Kscore prostate cancer test, which received FDA supplemental approval in Q2 2025. The company develops and commercializes medicines, including Rayaldee for secondary hyperparathyroidism and NGENLA for pediatric growth hormone deficiency, approved in over 40 markets through a partnership with Pfizer. OPKO Health also has a pipeline of molecules, biosimilars, and biologics targeting metabolic disorders, endocrinology, and oncology.

OPKO Health has a global presence with operations in the United States, Ireland, Chile, Spain, Israel, Mexico, Canada, and Australia. It has established pharmaceutical platforms in Spain, Ireland, Chile, and Mexico. Its diagnostic operations, through BioReference Laboratories, extend into Latin America, serving customers in Mexico, Brazil, and Argentina.

OPKO Health's brand reputation has been mixed, with a consensus rating of "Hold" from analysts. Strategic divestitures and a focus on drug development aim to improve financial standing. Pipeline progress and partnerships, including collaborations with Pfizer and Merck, contribute positively to its scientific reputation. The FDA approval of the 4Kscore test enhances its diagnostic offerings. While Q3 2025 earnings beat estimates, the year-over-year revenue decline presents challenges.

OPKO Health has a mixed ownership structure, with significant holdings by institutional and individual investors, particularly insiders. Major institutional owners include Rubric Capital Management LP, Vanguard Group Inc, and BlackRock, Inc. Individual insiders hold approximately 42% of the company's shares, with Phillip Frost (CEO) being the largest individual shareholder, owning 29% of shares outstanding.